By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aerpio Therapeutics 

9987 Carver Road
Suite 420
Cincinnati  Ohio  45242  U.S.A.
Phone: 513-985-1920 Fax: 513-985-0999


Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.

Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.

The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.

Key Statistics

Ownership: Private

Web Site: Aerpio
Employees: n/a


Company News
Aerpio Reports Second Quarter 2017 Financial Results 8/14/2017 6:19:43 AM
Aerpio Commences Trading On The OTCQB Market 8/9/2017 7:45:49 AM
Aerpio Commences Trading On The OTCQB Market 8/8/2017 11:57:37 AM
Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy 6/29/2017 9:50:52 AM
Aerpio Reports First Quarter 2017 Financial Results 5/16/2017 6:44:24 AM
Akebia (AKBA) Spinoff Aerpio Scores $40 Million 3/16/2017 6:33:20 AM
Aerpio Raises $40 Million 3/16/2017 6:09:08 AM
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD) 9/26/2016 11:20:53 AM
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial 6/13/2016 10:28:06 AM
Aerpio Announces Presentation Of Positive Results Of AKB-9778 In Patients With Diabetic Retinopathy From TIME-2 Phase IIa Study 2/10/2016 10:34:50 AM